Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Palofer 0.25mg / 5ml injection

Ferron Par Pharmaceuticals

Ingredients in every 5 ml

Palonosetron HCl 0.25 mg

Each package contains

1 vial of 5 ml

Dosage form

injection

Dosage formInjection

Flavour

None

W.H.O. classification

A04A
A04A

A.T.C. Level 1

Anatomical Main group

A - Alimentary tract and metabolism
A04A

A.T.C. Level 2

Therapeutic subgroup

A04 - Antiemetics and Antinauseants
A04A

A.T.C. Level 3

Pharmacological subgroup

A04A - Antiemetics and Antinauseants

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Indication

– The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy.
– The prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Dosage

18 YEARS OLD AND ABOVE
250 micrograms palonosetron as single intravenous bolus.
Applied approximately 30 minutes before the start of chemotherapy. Palonosetron should be injected over 30 seconds.

Repeated dosing of palonosetron within a seven day interval is not recommended. The efficacy of palonosetron in the prevention of nausea and vomiting induced by highly emetogenic chemotherapy may be enhanced by the addition of corticosteroid administered prior to chemotherapy.

UP TO 18 YEARS
Use in patients younger than 18 is not recommended until further data is available.

ELDERLY PATIENTS
No dose adjustment is necessary for the elderly

PATIENTS WITH HEPATIC IMPAIRMENT
No dose adjustment is necessary for patients with impaired hepatic function.

PATIENTS WITH RENAL IMPAIRMENT
No dose adjustment is necessary for patients with impaired renal function. No data are available for patients with end stage renal disease undergoing hemodialysis.